Cancer Research AACR Conference on Molecular Diagnostics - 2008  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 57, 1678-1681, May 1, 1997]
© 1997 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Issa, J.-P. J.
Right arrow Articles by Baylin, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Issa, J.-P. J.
Right arrow Articles by Baylin, S. B.

HIC1 Hypermethylation Is a Late Event in Hematopoietic Neoplasms1

Jean-Pierre J. Issa2, Barbara A. Zehnbauer3, Scott H. Kaufmann4, Maggie A. Biel and Stephen B. Baylin

The Oncology Center [J-P. J. I., B. A. Z., S. H. K., M. A. B., S. B. B.] and the Department of Medicine [S. B. B.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231

HIC1, a candidate tumor suppressor gene on 17p13.3, is hypermethylated and silenced in a large number of solid tumors. To determine its potential role in leukemias, we studied its methylation status in normal and neoplastic hematopoietic cells. We found HIC1 to be unmethylated in peripheral blood cells, bone marrow cells, and CD34+ cells. HIC1 was rarely methylated in newly diagnosed acute myelogenous leukemias (10%) but was relatively frequently methylated in newly diagnosed non-Hodgkin's lymphoma (25%), acute lymphocytic leukemia (ALL; 53%), and chronic-phase chronic myelogenous leukemia (50%). By contrast, HIC1 was hypermethylated in 100% of recurrent ALL and 100% of blast crisis chronic myelogenous leukemia. In two patients with ALL for whom paired diagnosis/relapse samples were available, HIC1 was unmethylated at diagnosis but was highly methylated at relapse after a chemotherapy-induced complete remission. HIC1 methylation, therefore, seems to be a progression event in hematopoietic neoplasms.

1 Supported by a Young Investigator Award from The American Society of Clinical Oncology (to J-P. J. I.) as well as NIH Grant 5RO1CA43318. S. H. K. is a scholar of the Leukemia Society of America.

2 To whom correspondence should be addressed, at The Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231.

3 Current address: Washington University, Pediatric Genetics, Box 8116, I Children's Place, St. Louis, MO 63110.

4 Current address: Mayo Clinic, 1301 Guggenheim, 200 First Street SW, Rochester, MN 55905.

Received 2/13/97. Accepted 3/17/97.




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. H. Vermeer, R. van Doorn, R. Dijkman, X. Mao, S. Whittaker, P. C. van Voorst Vader, M.-J. P. Gerritsen, M.-L. Geerts, S. Gellrich, O. Soderberg, et al.
Novel and Highly Recurrent Chromosomal Alterations in Sezary Syndrome
Cancer Res., April 15, 2008; 68(8): 2689 - 2698.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. R. L. Young, C. Mumaw, J. A. Marrs, and D. G. Skalnik
Antisense Targeting of CXXC Finger Protein 1 Inhibits Genomic Cytosine Methylation and Primitive Hematopoiesis in Zebrafish
J. Biol. Chem., December 1, 2006; 281(48): 37034 - 37044.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Rathi, A. K. Virmani, K. Harada, C. F. Timmons, K. Miyajima, R. J. Hay, D. Mastrangelo, A. Maitra, G. E. Tomlinson, and A. F. Gazdar
Aberrant Methylation of the HIC1 Promoter Is a Frequent Event in Specific Pediatric Neoplasms
Clin. Cancer Res., September 1, 2003; 9(10): 3674 - 3678.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. A. Palmisano, K. P. Crume, M. J. Grimes, S. A. Winters, M. Toyota, M. Esteller, N. Joste, S. B. Baylin, and S. A. Belinsky
Aberrant Promoter Methylation of the Transcription Factor Genes PAX5 {alpha} and {beta} in Human Cancers
Cancer Res., August 1, 2003; 63(15): 4620 - 4625.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. R. Rood, H. Zhang, D. M. Weitman, and P. H. Cogen
Hypermethylation of HIC-1 and 17p Allelic Loss in Medulloblastoma
Cancer Res., July 1, 2002; 62(13): 3794 - 3797.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Garcia-Manero, J. Daniel, T. L. Smith, S. M. Kornblau, M.-S. Lee, H. M. Kantarjian, and J.-P. J. Issa
DNA Methylation of Multiple Promoter-associated CpG Islands in Adult Acute Lymphocytic Leukemia
Clin. Cancer Res., July 1, 2002; 8(7): 2217 - 2224.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Garcia-Manero, C. Bueso-Ramos, J. Daniel, J. Williamson, H. M. Kantarjian, and J.-P. J. Issa
DNA Methylation Patterns at Relapse in Adult Acute Lymphocytic Leukemia
Clin. Cancer Res., June 1, 2002; 8(6): 1897 - 1903.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. M. Dong, H.-S. Kim, S.-H. Rha, and D. Sidransky
Promoter Hypermethylation of Multiple Genes in Carcinoma of the Uterine Cervix
Clin. Cancer Res., July 1, 2001; 7(7): 1982 - 1986.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. J. Rush, Z. Dai, D. J. Smiraglia, X. Gao, F. A. Wright, M. Fruhwald, J. F. Costello, W. A. Held, L. Yu, R. Krahe, et al.
Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci
Blood, May 15, 2001; 97(10): 3226 - 3233.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Toyota, K. J. Kopecky, M.-O. Toyota, K.-W. Jair, C. L. Willman, and J.-P. J. Issa
Methylation profiling in acute myeloid leukemia
Blood, May 1, 2001; 97(9): 2823 - 2829.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
M. G. Carter, M. A. Johns, X. Zeng, L. Zhou, M. C. Zink, J. L. Mankowski, D. M. Donovan, and S. B. Baylin
Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome
Hum. Mol. Genet., February 12, 2000; 9(3): 413 - 419.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. R. Melki, P. C. Vincent, and S. J. Clark
Concurrent DNA Hypermethylation of Multiple Genes in Acute Myeloid Leukemia
Cancer Res., August 1, 1999; 59(15): 3730 - 3740.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Aggerholm, P. Guldberg, M. Hokland, and P. Hokland
Extensive Intra- and Interindividual Heterogeneity of p15INK4B Methylation in Acute Myeloid Leukemia
Cancer Res., January 1, 1999; 59(2): 436 - 441.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Guerardel, S. Deltour, S. Pinte, D. Monte, A. Begue, A. K. Godwin, and D. Leprince
Identification in the Human Candidate Tumor Suppressor Gene HIC-1 of a New Major Alternative TATA-less Promoter Positively Regulated by p53
J. Biol. Chem., January 26, 2001; 276(5): 3078 - 3089.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1997 by the American Association for Cancer Research.